Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Sex-Based Differences in Risk of Serious Events with Individual Cholinesterase Inhibitors Use in Older Adults with Dementia: A Medicare Study

Speaker(s)

Masurkar P1, Chatterjee S2, Sherer JT3, Chen H3, Johnson ML3, Aparasu RR3
1University of Houston College of Pharmacy, Wylie, TX, USA, 2Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, houston, TX, USA, 3University of Houston, College of Pharmacy, Houston, TX, USA

OBJECTIVES: There is limited research evaluating the safety of Cholinesterase inhibitors (ChEIs) based on real-world data. Additionally, the moderating effect of sex on outcomes is not well-studied in dementia. This study evaluated the sex-based effects on the risk of serious events with individual ChEIs in older adults with dementia.

METHODS: This was a retrospective cohort study of patients ≥65 years with a dementia diagnosis using 2013-2015 Medicare claims data. Patients were selected with incident use of ChEIs, namely donepezil, galantamine, or rivastigmine, with a six-month washout period. The primary outcome of interest was serious events defined as Emergency Department visits, inpatient hospitalizations, or death within six months of ChEI initiation. Cumulative incidence functions curves, Gray’s test, and Fine and Gray’s proportional sub-distribution hazard model with inverse probability of treatment weighting(IPTW) generated using generalized boosted models(GBM) were used to assess sex-based effects on the risk of serious events across individual ChEIs.

RESULTS: The study included 767,684 older adults with dementia who were incident users of ChEIs (donepezil 79.42%, rivastigmine 17.67 %, galantamine 2.91%). There were 68.29% women and 31.70% men in the cohort. Fine and Gray’s proportional sub-distribution hazard model revealed that Rivastigmine(aHR 1.14; 95% CI, 1.09-1.18) and galantamine(aHR 1.52; 95% CI, 1.26 - 1.75) were associated with an increased risk of serious events compared to donepezil. However, sex-based interaction effects with ChEIs were significant. The stratified analysis found that women using rivastigmine (aHR 1.18; 95% CI, 1.06 - 1.31) were at increased risk of serious events compared to women using donepezil. Men using galantamine (aHR 1.71; 95% CI, 1.17-2.51) were at increased risk of serious events compared to men using donepezil.

CONCLUSIONS: This study found that the risk of serious events differs across sex. The study findings highlight the moderation effect of sex on ChEIs to assist providers in delivering personalized care in dementia

Code

RWD18

Topic

Epidemiology & Public Health, Study Approaches

Topic Subcategory

Safety & Pharmacoepidemiology

Disease

Geriatrics, Neurological Disorders, Personalized and Precision Medicine